SynthesisBMC musculoskeletal disorders2025
Efficacy of denosumab in treatment of osteoporosis in patients with rheumatoid arthritis: a meta-analysis of randomized controlled trial.
Synthesis in BMC musculoskeletal disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Comparison of the effects of denosumab and alendronate on fracture risk and bone metabolism in postmenopausal rheumatoid arthritis patients treated with oral glucocorticoids: A propensity score-matched retrospective cohort study.Therapeutic advances in musculoskeletal disease · 2026Article
- Ambiguities in the effect of physical activity on bone remodelling in spondyloarthritis.Reumatologia · 2026Review
- Does the Use of Denosumab in Combination with bDMARDs or tsDMARDs Increase the Risk of Infection in Patients with Osteoporosis and Inflammatory Rheumatic Diseases?Journal of clinical medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRheumatoid arthritis (RA) can lead to significant bone destruction, which may occur locally near inflamed joints or systemically. As patients age, they often experience increased bone erosion around affected joints, heightened osteoclast activity, and systemic inflammation, which collectively result in bone loss. This condition is commonly referred to as osteopenia or osteoporosis.
methodsA systematic search was conducted across multiple databases, including PubMed, Web of Science, Embase, and the Cochrane Library, to identify randomized controlled trials (RCTs) published on the use of denosumab in treating osteoporosis in patients with rheumatoid arthritis. The primary focus was to evaluate the impact of denosumab on various clinical measures, including bone mineral density (BMD), joint erosion scores, and overall joint maintenance. We performed a meta-analysis of six selected studies, all of which utilized these common metrics. The number of studies included in the analysis of each outcome varied depending on data availability in the original studies, with all included studies meeting our quality assessment criteria.
resultsThe results from these studies suggest that denosumab is effective in preventing further joint damage and bone loss in rheumatoid arthritis patients with osteoporosis. The data revealed a significant improvement in BMD, joint erosion scores, and joint narrowing scores in patients treated with denosumab compared to controls. These findings indicate the potential of denosumab as a preventive treatment for joint deterioration in RA patients with osteoporosis.
conclusionDenosumab demonstrates promising efficacy in maintaining bone health and preventing joint damage in rheumatoid arthritis patients with coexisting osteoporosis. However, further studies with larger sample sizes and long-term follow-up are necessary to confirm these findings and to comprehensively assess the long-term safety profile, including potential adverse events such as hypocalcemia, osteonecrosis of the jaw, and atypical femoral fractures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.